Rhythm Pharmaceuticals' lead drug scores in pivotal rare obesity trials
Less than two years after making its public debut, Boston biotech Rhythm Pharmaceuticals’ lead experimental drug has cleared two pivotal studies in patients with rare, genetic obesity disorders.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 157,400+ biopharma pros reading Endpoints daily — and it's free.